CombiGene’s epilepsy project reaches milestones according to plan
During early 2017 a successful dose-response study which gave the company valuable information was completed. Compared to other forms of treatment, gene therapy is unique in that the drug is administered to the patient only once, after which the body, itself, continues the treatment. It was therefore important for the company to understand how much of the medication the body will produce after receiving a given dose of gene therapy. In the dose-response study various doses of CG01 were tested, giving a clear indication of which doses are needed to suppress epileptic seizures.
A decisive preclinical proof-of-concept study, the long-term study for CG01 commenced during the second quarter of 2017 and was led by Professor Merab Kokaia, one of CombiGene’s scientific founders. For the long-term study to succeed, it is vital that the test models used simulate the human condition as closely as possible. At Professor Kokaia’s laboratory at Lund University there is a model that does just that. The model simulates human temporal lobe epilepsy, which makes it ideal for testing the antiepileptic effects of CombiGene’s candidate drug CG01. The model includes use of MR scanning (magnetic resonance) and EEG monitoring (electroencephalography) i.e., the same methods that are used to examine patients at a clinic. Preliminary results from the study is expected to be ready during the last quarter of 2017.